VUEWAY ® injection, a macrocyclic gadolinium-based contrast agent (GBCA), offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 mmol/kg) compared to other macrocyclic GBCAs for ...
Gadopiclenol only requires half of the gadolinium dose of conventional nonspecific GBCAs. Elucirem ™ (gadopiclenol) and Vueway ™ (gadopiclenol) are now available for use with magnetic resonance ...
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
The PROMISE study was a prospective, multinational, crossover (within-patient), double-blind comparison of the safety and efficacy of 0.05 mmol/kg gadopiclenol (VUEWAY) with 0.1 mmol/kg gadobutrol ...
VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
PRINCETON, N.J., Nov. 25, 2025 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that the U.S. Food and Drug ...
The benefit-risk ratio of Vueway considered positive in children from birth MILAN, Dec. 19, 2025 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on 11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback